193 related articles for article (PubMed ID: 30342424)
1. Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.
Nozal V; Martinez A
Eur J Med Chem; 2019 Jan; 161():39-47. PubMed ID: 30342424
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Regulation and Diverse Activities of Tau-Tubulin Kinase (TTBK) Isoforms.
Bao C; Bajrami B; Marcotte DJ; Chodaparambil JV; Kerns HM; Henderson J; Wei R; Gao B; Dillon GM
Cell Mol Neurobiol; 2021 May; 41(4):669-685. PubMed ID: 32424773
[TBL] [Abstract][Full Text] [Related]
3. Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis.
Bashore FM; Marquez AB; Chaikuad A; Howell S; Dunn AS; Beltran AA; Smith JL; Drewry DH; Beltran AS; Axtman AD
Sci Rep; 2023 Apr; 13(1):6118. PubMed ID: 37059819
[TBL] [Abstract][Full Text] [Related]
4. The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor.
Marcotte DJ; Spilker KA; Wen D; Hesson T; Patterson TA; Kumar PR; Chodaparambil JV
Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):103-108. PubMed ID: 32133995
[TBL] [Abstract][Full Text] [Related]
5. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.
Taylor LM; McMillan PJ; Liachko NF; Strovas TJ; Ghetti B; Bird TD; Keene CD; Kraemer BC
Mol Neurodegener; 2018 Feb; 13(1):7. PubMed ID: 29409526
[TBL] [Abstract][Full Text] [Related]
6. Tau tubulin kinases in proteinopathy.
Taylor LM; McMillan PJ; Kraemer BC; Liachko NF
FEBS J; 2019 Jul; 286(13):2434-2446. PubMed ID: 31034749
[TBL] [Abstract][Full Text] [Related]
7. Adult onset pan-neuronal human tau tubulin kinase 1 expression causes severe cerebellar neurodegeneration in mice.
McMillan P; Wheeler J; Gatlin RE; Taylor L; Strovas T; Baum M; Bird TD; Latimer C; Keene CD; Kraemer BC; Liachko NF
Acta Neuropathol Commun; 2020 Nov; 8(1):200. PubMed ID: 33228809
[TBL] [Abstract][Full Text] [Related]
8. Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites.
Dillon GM; Henderson JL; Bao C; Joyce JA; Calhoun M; Amaral B; King KW; Bajrami B; Rabah D
PLoS One; 2020; 15(4):e0228771. PubMed ID: 32255788
[TBL] [Abstract][Full Text] [Related]
9. X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors.
Xue Y; Wan PT; Hillertz P; Schweikart F; Zhao Y; Wissler L; Dekker N
ChemMedChem; 2013 Nov; 8(11):1846-54. PubMed ID: 24039150
[TBL] [Abstract][Full Text] [Related]
10. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.
Sato S; Cerny RL; Buescher JL; Ikezu T
J Neurochem; 2006 Sep; 98(5):1573-84. PubMed ID: 16923168
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo.
Halkina T; Henderson JL; Lin EY; Himmelbauer MK; Jones JH; Nevalainen M; Feng J; King K; Rooney M; Johnson JL; Marcotte DJ; Chodaparambil JV; Kumar PR; Patterson TA; Murugan P; Schuman E; Wong L; Hesson T; Lamore S; Bao C; Calhoun M; Certo H; Amaral B; Dillon GM; Gilfillan R; de Turiso FG
J Med Chem; 2021 May; 64(9):6358-6380. PubMed ID: 33944571
[TBL] [Abstract][Full Text] [Related]
12. Tau-tubulin kinase.
Ikezu S; Ikezu T
Front Mol Neurosci; 2014; 7():33. PubMed ID: 24808823
[TBL] [Abstract][Full Text] [Related]
13. TTBK2: a tau protein kinase beyond tau phosphorylation.
Liao JC; Yang TT; Weng RR; Kuo CT; Chang CW
Biomed Res Int; 2015; 2015():575170. PubMed ID: 25950000
[TBL] [Abstract][Full Text] [Related]
14. TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Nozal V; Martínez-González L; Gomez-Almeria M; Gonzalo-Consuegra C; Santana P; Chaikuad A; Pérez-Cuevas E; Knapp S; Lietha D; Ramírez D; Petralla S; Monti B; Gil C; Martín-Requero A; Palomo V; de Lago E; Martinez A
J Med Chem; 2022 Jan; 65(2):1585-1607. PubMed ID: 34978799
[TBL] [Abstract][Full Text] [Related]
15. The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor.
Kiefer SE; Chang CJ; Kimura SR; Gao M; Xie D; Zhang Y; Zhang G; Gill MB; Mastalerz H; Thompson LA; Cacace AM; Sheriff S
Acta Crystallogr F Struct Biol Commun; 2014 Feb; 70(Pt 2):173-81. PubMed ID: 24637750
[TBL] [Abstract][Full Text] [Related]
16. Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation.
Jana S; Singh SK
J Biomol Struct Dyn; 2020 Feb; 38(3):886-900. PubMed ID: 30829560
[TBL] [Abstract][Full Text] [Related]
17. Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions.
Cuny GD
Curr Pharm Des; 2009; 15(34):3919-39. PubMed ID: 19751204
[TBL] [Abstract][Full Text] [Related]
18. The structural, functional, and dynamic effect of Tau tubulin kinase1 upon a mutation: A neuro-degenerative hotspot.
Ahamad S; Hema K; Kumar V; Gupta D
J Cell Biochem; 2021 Nov; 122(11):1653-1664. PubMed ID: 34297427
[TBL] [Abstract][Full Text] [Related]
19. Human TTBK1, TTBK2 and MARK1 kinase toxicity in
Fernius J; Starkenberg A; Pokrzywa M; Thor S
Biol Open; 2017 Jul; 6(7):1013-1023. PubMed ID: 28711868
[TBL] [Abstract][Full Text] [Related]
20. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
